Skip to main content

Catalyst Calendar

Scope

Thu, Oct 1, 2026

1 updates
CGEM
7:30 PM

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC After agreement with the U.S. FDA, Real-Time Oncology Review program submission process initiated; completion of NDA

cullinantherapeutics.com

Thu, Sep 24, 2026

1 updates
CGEM
7:00 AM

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren’s disease in December CLN-049 (FLT3 TCE) updated data from the Phase 1 dose escalation study in December CAMBRIDGE, Mass., Sept.

Presentation / Abstract • Phase 1ACR Convergence 2026 poster session Sun, Nov 8, 2026, 10:30 AM ETcullinantherapeutics.com

Mon, Sep 21, 2026

1 updates

Mon, Sep 14, 2026

1 updates
CGEM
7:00 AM

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Company to host a virtual event today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases

Results Call • Phase 3Results call Mon, Sep 14, 2026, 8:00 AM ETcullinantherapeutics.com

Sun, Sep 13, 2026

1 updates
CGEM
7:15 PM

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Results from the Phase 3 REZILIENT3 trial were featured in a Presidential Symposium at WCLC 2026 and demonstrated a statistically significant improvement in progression-free survival in first-line EGFR exon 20 insertion mutation NSCLC at a planned interim analysis PRINCETON, N.J., TOKYO, Japan,

Trial Results • Phase 3WCLC Presidential Symposium presentation Mon, Sep 14, 2026, 8:00 AM KSTcullinantherapeutics.com

Thu, Sep 10, 2026

1 updates
CGEM
1:00 PM

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, September 13, 2026 Company to host a virtual event on Monday, September 14, 2026, at

Results Call • Phase 3Results call Mon, Sep 14, 2026, 8:00 AM ETcullinantherapeutics.com

Wed, Aug 19, 2026

1 updates
CGEM
12:00 PM

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLC PRINCETON, N.J., CAMBRIDGE, Mass., August 19, 2026 — Taiho Oncology, Inc.

Presentation / Abstract • Phase 3Presidential Symposium presentation Mon, Sep 14, 2026, 8:00 AM KSTcullinantherapeutics.com

Wed, Aug 12, 2026

1 updates
CGEM
7:30 PM

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

PRINCETON, New Jersey, TOKYO, Japan, CAMBRIDGE, Mass., August 12, 2026 — Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib and

Trial Results • Phase 3REZILIENT3 interim analysis results Wed, Aug 12, 2026cullinantherapeutics.com

Thu, Aug 6, 2026

1 updates

Tue, Jul 28, 2026

1 updates